Dividend King Growth Giant: J&J Faces Lilly Challenge
Johnson & Johnson and Eli Lilly reported contrasting Q1 2026 results, pitting a durable, dividend-focused giant again...
Zero-based budgeting vs traditional budgeting highlights how every dollar is assigned in the former, offering tighter control over spending.
20,533 articlesJohnson & Johnson and Eli Lilly reported contrasting Q1 2026 results, pitting a durable, dividend-focused giant again...
A Chinese AI model is reported to rival US leaders in performance, sparking a reassessment of investments in data cen...
AI-driven datacenters are pushing power demands higher, forcing a rethink of power distribution. Analysts flag musash...
Five years after a split investment in Bitcoin and XRP, the outcomes diverged dramatically amid regulation and instit...
Prediction markets show divergent odds for Stripe, Discord, and Anduril IPOs as of July 2026. Traders weigh S-1 timin...
As Berkshire's new leader, Greg Abel faces a massive cash pile. This article examines why Alphabet is the target, wha...
Eli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
Intel's turnaround gains traction amid AI-driven demand and a narrowing foundry loss gap, fueling a debate about whet...
If Honeywell were to split into focused companies, which segments would win the most? This guide provides a practical...
A new approach to retirement income uses a dividend growth roadmap that prioritizes rising payouts over static yields...
As the crypto bill enters its final stretch, democratic opposition clarity grows. Lawmakers argue the measure needs s...
In 2026, JEPI remains a go-to for retirement income, yet Amplify DIVO is delivering stronger total returns for some i...